Proton Pump Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Proton Pump Inhibitors Market is Segmented by Drug Type (OTC Drugs (Omeprazole, Lansoprazole, Esomeprazole, and Other OTC Drugs) and Prescription Drugs (Rabeprazole, Dexlansoprazole, Pantoprazole, and Other Prescription Drugs) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Proton Pump Inhibitors Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The proton pump inhibitors market is poised to grow at a CAGR of 4.5% during the forecast period, 2022-2027.

Many researchers have found that proton pump inhibitors have increased the risk of COVID-19 in patients taking these medications. The article titled "Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors" published in August 2020, reported that more than 53,000 people taking proton pump inhibitors participated, out of which 3,386 said that they had tested positive for COVID-19. This factor is expected to affect the market growth as patients undergoing proton-pump inhibitor therapy are advised to consume fewer medications and avoid these medications unless it is an emergency. Thus, COVID-19 has a significant impact on the growth of the studied market.

Proton pump inhibitors are the gold standard medication for gastroesophageal reflux disease (GERD), and the increasing prevalence of GERD and the rising acceptance of novel drug delivery systems are the two most prominent factors driving the growth of the market.

Additionally, the risk factors such as aging, obesity, delayed stomach emptying, changing lifestyles associated with smoking, and consumption of alcohol, coffee, fatty, and fried foods are the major reasons for the occurrence of GERD. Furthermore, the United Nations Report titled "World Population Ageing Report, 2020 Highlights, there were 727 million people aged 65 years or over in the global population, and this number is positioned to double to 1.5 billion in 2050.

Furthermore, players in this market are developing novel products and coming up with new product launches to leverage market opportunities. For instance, in March 2021, Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20mg, generic for Prilose. Such a launch of drugs is propelling the growth of the market.

Thus, the increasing prevalence of GERD, along with the growing risk factor population, is likely to increase the demand for proton pump inhibitors, which is expected to drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitor market. However, the increasing use of generic products in the market and the side effects associated with the drugs may hamper the market growth.

Scope of the Report

As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The proton pump inhibitors market is segmented by drug type (OTC Drugs (omeprazole, lansoprazole, esomeprazole, and other OTC drugs) and prescription drugs (rabeprazole, dexlansoprazole, pantoprazole, and other prescription drugs) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions. The report offers the market sizes and forecasts in value (USD million) for the above segments.

By Drug Type
OTC (Over-the-counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Esomeprazole Segment is Expected to Account for a Significant Share Over the Forecast Period

Esomeprazole is expected to have a significant share of the revenue as it is mostly indicated to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug shortly.

In addition, major market players are focused on research and development and market expansion activities to bring new and reliable formulations to the market. For instance, in July 2020, Cadila Pharmaceuticals launched esomeprazole tablets for the treatment of hyperacidity and drug-induced gastritis under the brand name Esiloc in India.

Additionally, the strategic initiatives taken by the market players are propelling the growth of the segment. For instance, in March 2021, Daiichi Sankyo Co., Ltd. transferred the marketing and distribution rights for the proton pump inhibitor Nexium capsules 10 mg and 20 mg and Nexium granules for suspension 10 mg and 20 mg (esomeprazole magnesium) to AstraZeneca in Japan.

Thus, owing to all the above-mentioned factors, the Esomeprazole segment is expected to achieve high growth rates.

GERD

North America is Expected to Account for the Large Share of the Market

North America currently dominates the proton pump inhibitors market and is anticipated to show a similar trend over the forecast period without significant fluctuations. There is a rising burden of GERD in the United States, Canada, and Mexico due to people’s shift toward unhealthy lifestyles. As per the National Institute of Diabetes and Digestive and Kidney Diseases Statistics of 2020, about 20% of people in the United States have GERD.

In the United States, proton pump inhibitors are one of the most widely prescribed drugs, and increased PPI use has been observed in United States ambulatory settings for the last few years. Furthermore, many firms are spending heavily on promoting their brands. The widespread use of PPIs has also gained the attention of the American Board of Internal Medicine; as a result, the board conducted a campaign to promote the appropriate use of PPIs.

Moreover, product launches in generic categories are also expected to impact the market. For instance, in February 2021, Dr. Reddy’s Laboratories Ltd. launched lansoprazole DR, orally disintegrating tablets, a therapeutic equivalent generic version of Prevacid soluTab delayed-release orally disintegrating tablets, 15 mg and 30 mg, approved by the United States Food and Drug Administration (USFDA). Such generic drug launches are also propelling the growth of the market.

Thus, owing to the abovementioned factors, the proton pump inhibitor market in the North American region is expected to project growth over the forecast period.

Proton Pump Inhibitors Market Growth

Competitive Landscape

The proton pump inhibitors market is moderately competitive, owing to the presence of various players in the market. The market players are focusing on acquiring market shares by focusing on aggressive advertisements and awareness programs among patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer, among others.

Recent Developments

  • In April 2022, Daewon Pharmaceutical launched Escorten, one of the first proton-pump inhibitor drugs in Korea. It is an esomeprazole magnesium trihydrate available in 10mg.
  • In January 2022, TWI Pharmaceuticals USA launched the generic formulation of Dexilant in the United States. It is a dexlansoprazole used to treat heartburn caused by GERD (Gastroesophageal Reflux Disease) and to heal erosive esophagitis. It is available as dexlansoprazole delayed release 30mg and 60mg capsules.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Gastroesophageal Reflux Disease (GERD)

      2. 4.2.2 Rising Acceptance of Novel Drug Delivery Systems

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Use of Generic Products

      2. 4.3.2 Side Effects Related to Proton Pump Inhibitors

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 OTC (Over-the-counter) Drugs

        1. 5.1.1.1 Omeprazole

        2. 5.1.1.2 Lansoprazole

        3. 5.1.1.3 Esomeprazole

        4. 5.1.1.4 Other OTC Drugs

      2. 5.1.2 Prescription Drugs

        1. 5.1.2.1 Rabeprazole

        2. 5.1.2.2 Dexlansoprazole

        3. 5.1.2.3 Pantoprazole

        4. 5.1.2.4 Other Prescription Drugs

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Bayer AG

      3. 6.1.3 Cadila Pharmaceuticals

      4. 6.1.4 Eli Lilly and Company

      5. 6.1.5 Eisai Inc.

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Santarus Inc.

      10. 6.1.10 Takeda Pharmaceuticals

      11. 6.1.11 Eisai Pharmaceuticals India Pvt. Ltd

      12. 6.1.12 Wyeth LLC

      13. 6.1.13 Sanofi SA

      14. 6.1.14 Perrigo Company PLC

      15. 6.1.15 Dr. Reddy's Laboratories

      16. 6.1.16 Aralez Pharmaceuticals Inc.

      17. 6.1.17 Redhill Pharma Limited

      18. 6.1.18 Cipla Limited

      19. 6.1.19 Changzhou Siyao Pharmaceuticals

      20. 6.1.20 Yangzhou Pharmaceutical

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Proton Pump Inhibitors Market market is studied from 2019 - 2027.

The Global Proton Pump Inhibitors Market is growing at a CAGR of 4.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bayer AG, Pfizer Inc., Takeda Pharmaceuticals, Cadila Pharmaceuticals, AstraZeneca are the major companies operating in Global Proton Pump Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!